SCYNEXIS, Inc. is a biotechnology company developing innovative medicines to treat and prevent difficult-to-treat and drug-resistant fungal infections. The company's lead product, ibrexafungerp, is approved for the treatment of vulvovaginal candidiasis and is being investigated for life-threatening invasive fungal infections.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.